Add-on to Chemoradiotherapy Doubles NSCLC Survival for Some Veterans

ANN ARBOR, MI – Median overall survival doubled for veterans with stage III non-small cell lung cancer who received chemoradiotherapy plus durvalumab, as compared to those receiving chemoradiotherapy alone, according to a new study. The authors note that the current standard of care for patients with unresectable stage III NSCLC is concurrent chemoradiotherapy followed by durvalumab maintenance, but veterans were not included in the trial establishing that protocol.

Male Veterans With Breast Cancer Fare Worse Than Females

ALBANY, NY – While survival rates for breast cancer generally have improved over the last decades, that is not true for at least one cohort of patients: men. In fact, increased mortality has been documented for male veterans with breast cancer, even after adjusting for age and other clinical factors. VA researchers tried to determine why.

VA Dramatically Reduces ESA Use for Cancer-Related Anemia

COLUMBIA, SC -- Erythropoiesis-stimulating agents were indicated for use in patients with cancer who receive noncurative myelosuppressive chemotherapy, with the intention of mitigating symptoms and side effects to decrease the need for red blood cell transfusions....

ART Has Changed the Cancers Associated with HIV

New York—Antiretroviral therapy transformed infection with human immunodeficiency virus (HIV) from a death sentence to a chronic condition, along the way changing virtually everything about the disease, including its association with cancer. For years, specific...

Acute Kidney Injury Risk With Stem Cell Transplant

CHARLOTTESVILLE, VA – Hematopoietic stem cell transplantation can be a life-saving therapy for many patients with cancer, as well as patients with some nonmalignant hematologic disorders, such as aplastic anemia, sickle cell disease, and certain congenital immune...

Is Radiation Therapy Linked to Second Cancer Diagnoses?

STANFORD, CA – How likely is a second cancer diagnosis after primary cancer treatment with 3-dimensional conformal radiotherapy (3DCRT), intensity-modulated radiotherapy (IMRT), or proton beam radiotherapy (PBRT) for lymphoma and other cancers? Researchers from...

VA Has More Options as Treatment for Mantle Cell Lymphoma Expands Rapidly

Most patients with mantle cell lymphoma, which is considered a presumptive condition for veterans exposed to Agent Orange, face a rapidly progressive disease and higher mortality rates. New therapies are giving VA clinicians more options to help MCL patients. For example, the availability now of three Bruton tyrosine kinase [BTK] inhibitors is allowing treatment to be better matched to the needs of the patient.